Citigroup
RCUS icon

Citigroup’s Arcus Biosciences RCUS Stock Holding History

Citigroup’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$648K Hold
30,000
– – ﹤0.01% 3389
2025
Q4 		$715K Buy
30,000
+200
+0.7% +$4.08K ﹤0.01% 3361
2025
Q3 		$405K Hold
29,800
– – ﹤0.01% 3678
2025
Q2 		$243K Sell
29,800
-29,900
-50% -$255K ﹤0.01% 3975
2025
Q1 		$469K Buy
59,700
+29,800
+100% +$345K ﹤0.01% 3718
2024
Q4 		$445K Buy
+29,900
New +$488K ﹤0.01% 3913
2023
Q1 		– Sell
-20,000
Closed -$414K – 5796
2022
Q4 		$414K Buy
20,000
+2,000
+11% +$55K ﹤0.01% 3306
2022
Q3 		$471K Buy
18,000
+12,200
+210% +$323K ﹤0.01% 3272
2022
Q2 		$147K Sell
5,800
-1,700
-23% -$41.6K ﹤0.01% 4014
2022
Q1 		$237K Buy
+7,500
New +$251K ﹤0.01% 3989
2021
Q4 		– Sell
-50,500
Closed -$1.76M – 6049
2021
Q3 		$1.76M Buy
+50,500
New +$1.57M ﹤0.01% 2634

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Citigroup's RCUS Position: Q1 2026 in Review

Citigroup reduced its Arcus Biosciences (RCUS) stake by 18% in Q1 2026, selling an estimated $127K and leaving 26,396 shares worth $570K. The position accounts for ﹤0.01% of the portfolio, ranked #3466.

Citigroup first reported a position in RCUS in Q1 2018 and has held it in 33 quarters since. The position peaked at $6.42M in Q1 2023. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Citigroup held 26,396 shares of Arcus Biosciences worth $570K as of Q1 2026.
  • Citigroup sold 5,862 Arcus Biosciences shares in Q1 2026, an estimated $127K.
  • Arcus Biosciences made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3466 holding.
  • Citigroup first reported a position in Arcus Biosciences in Q1 2018 and has held it in 33 quarters since.
  • Citigroup's Arcus Biosciences position peaked at $6.42M in Q1 2023.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.